(CGEM) Cullinan Oncology - Overview
Stock: Zipalertinib, CLN-978, CLN-619, CLN-049, CLN-617
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 67.6% |
| Relative Tail Risk | -8.94% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.52 |
| Alpha | 4.06 |
| Character TTM | |
|---|---|
| Beta | 0.916 |
| Beta Downside | 0.260 |
| Drawdowns 3y | |
|---|---|
| Max DD | 80.41% |
| CAGR/Max DD | 0.03 |
Description: CGEM Cullinan Oncology December 27, 2025
Cullinan Therapeutics (NASDAQ: CGEM) is a clinical-stage biotech focused on small-molecule and biologic therapies for oncology and autoimmune disorders. Its lead assets include zipalertinib, a bioavailable inhibitor now in a Phase 3 trial for non-small cell lung cancer (NSCLC), and CLN-978, a T-cell engager targeting systemic lupus erythematosus and rheumatoid arthritis. Additional early-stage programs comprise CLN-619 (monoclonal antibody for solid tumors and multiple myeloma), CLN-049 (bispecific antibody for AML/MDS and MRD-positive AML), and CLN-617 (fusion protein for solid tumors). The company collaborates with Adimab on antibody discovery and with Taiho Pharmaceutical on zipalertinib co-development; it rebranded from Cullinan Oncology to Cullinan Therapeutics in April 2024.
Key sector context: the global NSCLC market is projected to exceed $30 billion by 2028, while biotech R&D spending averages a 12 % YoY increase, pressuring cash-burn rates for companies in Phase 3. Historically, Phase 3 oncology trials have a ~30 % success probability, implying a material valuation upside if zipalertinib meets its primary endpoint. As of the latest filing, CGEM reported $85 million in cash and equivalents, sufficient for roughly 12 months of runway at its current burn rate.
For a deeper, data-driven look at CGEM’s valuation and risk profile, check out the analyst page on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.36 > 0.02 and ΔFCF/TA -16.59 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.36 > 3% & CFO -174.3m > Net Income -216.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 10.45 > 1.5 & < 3 |
| Outstanding Shares: last quarter (59.0m) vs 12m ago 1.16% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: -11.97 > 6 (EBITDA TTM -236.1m / Interest Expense TTM -19.8m) |
Altman Z'' -15.00
| A: 0.64 (Total Current Assets 342.2m - Total Current Liabilities 32.8m) / Total Assets 484.1m |
| B: -1.11 (Retained Earnings -537.4m / Total Assets 484.1m) |
| C: -0.42 (EBIT TTM -236.5m / Avg Total Assets 568.7m) |
| D: -16.38 (Book Value of Equity -536.4m / Total Liabilities 32.8m) |
| Altman-Z'' Score: -19.41 = D |
What is the price of CGEM shares?
Over the past week, the price has changed by +2.26%, over one month by +20.37%, over three months by +66.39% and over the past year by +18.16%.
Is CGEM a buy, sell or hold?
- StrongBuy: 8
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CGEM price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 29.4 | 140.6% |
| Analysts Target Price | 29.4 | 140.6% |
| ValueRay Target Price | 13.7 | 11.8% |
CGEM Fundamental Data Overview February 03, 2026
P/S = 26.8794
P/B = 1.5601
Revenue TTM = 0.0 USD
EBIT TTM = -236.5m USD
EBITDA TTM = -236.1m USD
Long Term Debt = 1.19m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.19m USD (from shortTermDebt, last quarter)
Debt = 1.19m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -102.1m USD (from netDebt column, last quarter)
Enterprise Value = 375.1m USD (706.6m + Debt 1.19m - CCE 332.6m)
Interest Coverage Ratio = -11.97 (Ebit TTM -236.5m / Interest Expense TTM -19.8m)
EV/FCF = -2.15x (Enterprise Value 375.1m / FCF TTM -174.3m)
FCF Yield = -46.46% (FCF TTM -174.3m / Enterprise Value 375.1m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 230.0k) / Revenue TTM)
Tobins Q-Ratio = 0.77 (Enterprise Value 375.1m / Total Assets 484.1m)
Interest Expense / Debt = 388.5% (Interest Expense 4.62m / Debt 1.19m)
Taxrate = 21.0% (US default 21%)
NOPAT = -186.8m (EBIT -236.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 10.45 (Total Current Assets 342.2m / Total Current Liabilities 32.8m)
Debt / Equity = 0.00 (Debt 1.19m / totalStockholderEquity, last quarter 451.4m)
Debt / EBITDA = 0.43 (negative EBITDA) (Net Debt -102.1m / EBITDA -236.1m)
Debt / FCF = 0.59 (negative FCF - burning cash) (Net Debt -102.1m / FCF TTM -174.3m)
Total Stockholder Equity = 521.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -38.12% (Net Income -216.8m / Total Assets 484.1m)
RoE = -41.58% (Net Income TTM -216.8m / Total Stockholder Equity 521.4m)
RoCE = -45.24% (EBIT -236.5m / Capital Employed (Equity 521.4m + L.T.Debt 1.19m))
RoIC = -35.82% (negative operating profit) (NOPAT -186.8m / Invested Capital 521.4m)
WACC = 9.27% (E(706.6m)/V(707.7m) * Re(9.29%) + (debt cost/tax rate unavailable))
Discount Rate = 9.29% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 17.43%
Fair Price DCF = unknown (Cash Flow -174.3m)
EPS Correlation: -33.25 | EPS CAGR: 5.46% | SUE: 3.78 | # QB: 1
Revenue Correlation: 42.01 | Revenue CAGR: 89.54% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.91 | Chg30d=+0.000 | Revisions Net=+2 | Analysts=4
EPS next Year (2026-12-31): EPS=-3.32 | Chg30d=+0.000 | Revisions Net=+1 | Growth EPS=+8.0% | Growth Revenue=+231.7%